Overall, patients with RA who are treated with anti-TNF therapies are at an increased risk for infections and serious infections, including opportunistic infections, and screening for tuberculosis is recommended as described in the prescribing information [10–14]. This evidence concerns the gene TNF and rheumatoid arthritis.